EGFR and non-small cell lung carcinoma: Research suggests that vorinostat, which is a pan-histone deacetylase inhibitor (HDACi), can epigenetically restore BIM function and sensitivity of NSCLC cells expressing the BIM deletion polymorphism to EGFR-TKI [10].